**Summary:**
On September 21, 2020, the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, issued a notice regarding draft regulatory guidelines for vaccine development, with specific consideration for COVID-19 vaccines. Recognizing the complexity of vaccine development and India's role as a major global vaccine producer, the CDSCO has formulated these guidelines to provide clarity on regulatory requirements for vaccine developers. The guidelines, drafted under the Drugs and Cosmetics Rules, 1940, and the New Drugs and Clinical Trials Rules, 2019, take into account guidelines from the WHO, USFDA, EMA, and other applicable CDSCO guidelines. The aim is to facilitate the rapid development of safe, effective, and quality vaccines, particularly for COVID-19, within India. These guidelines are intended to reflect CDSCO's current perspective and are recommendatory, not replacing existing statutory requirements. Stakeholders were invited to submit comments on the draft guidelines by October 12, 2020, to dcinic.in and vgsidcigmail.com. The guidelines are intended to be dynamic and will be updated based on feedback and evolving scientific advancements to address implementation challenges and incorporate new methodologies for vaccine development. The notice was issued by Dr. V. G. Somani, Drugs Controller General of India.
Key Entities Referenced
Central Drugs Standard Control Organization: A national regulatory body for pharmaceuticals and medical devices in India.
COVID19 Vaccines: Vaccines specifically designed to protect against the COVID-19 disease.
Drugs and Cosmetics Rules, 1940: A set of rules in India governing the import, manufacture, distribution, and sale of drugs and cosmetics.
New Drugs and Clinical Trials Rules, 2019: A set of rules regulating clinical trials and new drug approvals in India.
WHO: World Health Organization, an international organization responsible for public health.
USFDA: United States Food and Drug Administration, the regulatory agency for food and drugs in the United States.
EMA: European Medicines Agency, a regulatory agency of the European Union responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.
Dr. V. G. Somani: Drugs Controller General of India
Central Drugs Standard Control Organization
Directorate General of Health Services
Ministry of Health and Family Welfare
Government of India
Date -21 sept 2020
NOTICE
Information on draft regulatory guidelines for development of
vaccines with special consideration for Covid -19 vaccines
Development of vaccine is a complex activity which involves multidisciplinary research
and generation of adequate laboratory, nonclinical and clinical data to ensure their
safety, efficacy and quality. India is one of the major producers of vaccines in the world
which cater the major portion of requirements of many vaccines globally.
In light of the present pandemic situation in the country, a need was felt to develop
comprehensive guidelines on vaccines developments which will provide clear
understanding of regulatory requirements to the vaccine developers.
Accordingly, CDSCO has prepared draft Guidelines for Development of Vaccines with
Special Consideration of COVID-19 Vaccines under Drugs and Cosmetics Rules, 1940
and New Drugs and Clinical Trials Rules,2019 in consideration of WHO, USFDA, and
EMA guidelines as well as other applicable guidelines of CDSCO to facilitate early
development of safe, effective and quality vaccines especially COVID-19 vaccines in
the country. The same is attached herewith for all concerned.
These guidelines reflect the current thinking of CDSCO and they may be followed for
development and regulatory approval of vaccines in India.
These guidelines are dynamic and recommendatory in nature and not meant to
override or replace statutory requirements. Comments , if any , may be forwarded till
12! oct 2020 on dci@nic.in and vgsidci@gmail.com. Accordingly, it will be further
updated and refined on need basis to address any challenges that may arise during
its implementation as well as to incorporate scientifically and technologically advanced
method, design, etc. for vaccine development as emerged from research in this area.
Dr. V. G. Somani
Drugs Controller General (India)